Cargando…

Plasma Levels of Matrix Metalloprotease MMP-9 and Tissue Inhibitor TIMP-1 in Caucasian Patients with Polypoidal Choroidal Vasculopathy

Background: Matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) are regulating enzymes of the extracellular matrix. A systemic imbalance of MMP-9 and TIMP-1, thought to reflect an imbalance of the extracellular matrix homeostasis, is previously associated with po...

Descripción completa

Detalles Bibliográficos
Autores principales: Sørensen, Jakob Ø., Subhi, Yousif, Molbech, Christopher R., Krogh Nielsen, Marie, Sørensen, Torben L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356191/
https://www.ncbi.nlm.nih.gov/pubmed/32429088
http://dx.doi.org/10.3390/vision4020027
_version_ 1783558443397808128
author Sørensen, Jakob Ø.
Subhi, Yousif
Molbech, Christopher R.
Krogh Nielsen, Marie
Sørensen, Torben L.
author_facet Sørensen, Jakob Ø.
Subhi, Yousif
Molbech, Christopher R.
Krogh Nielsen, Marie
Sørensen, Torben L.
author_sort Sørensen, Jakob Ø.
collection PubMed
description Background: Matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) are regulating enzymes of the extracellular matrix. A systemic imbalance of MMP-9 and TIMP-1, thought to reflect an imbalance of the extracellular matrix homeostasis, is previously associated with polypoidal choroidal vasculopathy (PCV) in Asian patients. Previous studies suggest inter-ethnical differences in the genetic background and etiology of PCV. To further explore this issue, we studied the plasma levels of MMP-9 and TIMP-1 in Caucasian patients with PCV and compared to healthy age-matched controls. Methods: For this prospective case-control study, 60 participants were recruited who were either patients with PCV (n = 26) or healthy controls (n = 34). All participants underwent detailed clinical examination. We sampled fresh venous blood, isolated plasma, and quantified plasma concentrations of the extracellular matrix regulators MMP-9 and TIMP-1 using electrochemiluminescence immunoassays. Results: Plasma levels of MMP-9 (p = 0.4), TIMP-1 (p = 0.9), and MMP-9/TIMP-1 ratio (p = 0.4) did not differ significantly between patients with PCV and healthy controls. No differences appeared after adjusting for influencing co-variates in multivariate analyses. Conclusion: We demonstrate that Caucasian patients with PCV do not have altered levels of plasma MMP-9 or plasma TIMP-1. These findings suggest no strong evidence of a systemic imbalance of the extracellular matrix homeostasis in Caucasian patients with PCV. Our findings are in line with studies of other aspects of PCV that are also subject to significant inter-ethnical differences.
format Online
Article
Text
id pubmed-7356191
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73561912020-07-31 Plasma Levels of Matrix Metalloprotease MMP-9 and Tissue Inhibitor TIMP-1 in Caucasian Patients with Polypoidal Choroidal Vasculopathy Sørensen, Jakob Ø. Subhi, Yousif Molbech, Christopher R. Krogh Nielsen, Marie Sørensen, Torben L. Vision (Basel) Article Background: Matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) are regulating enzymes of the extracellular matrix. A systemic imbalance of MMP-9 and TIMP-1, thought to reflect an imbalance of the extracellular matrix homeostasis, is previously associated with polypoidal choroidal vasculopathy (PCV) in Asian patients. Previous studies suggest inter-ethnical differences in the genetic background and etiology of PCV. To further explore this issue, we studied the plasma levels of MMP-9 and TIMP-1 in Caucasian patients with PCV and compared to healthy age-matched controls. Methods: For this prospective case-control study, 60 participants were recruited who were either patients with PCV (n = 26) or healthy controls (n = 34). All participants underwent detailed clinical examination. We sampled fresh venous blood, isolated plasma, and quantified plasma concentrations of the extracellular matrix regulators MMP-9 and TIMP-1 using electrochemiluminescence immunoassays. Results: Plasma levels of MMP-9 (p = 0.4), TIMP-1 (p = 0.9), and MMP-9/TIMP-1 ratio (p = 0.4) did not differ significantly between patients with PCV and healthy controls. No differences appeared after adjusting for influencing co-variates in multivariate analyses. Conclusion: We demonstrate that Caucasian patients with PCV do not have altered levels of plasma MMP-9 or plasma TIMP-1. These findings suggest no strong evidence of a systemic imbalance of the extracellular matrix homeostasis in Caucasian patients with PCV. Our findings are in line with studies of other aspects of PCV that are also subject to significant inter-ethnical differences. MDPI 2020-05-15 /pmc/articles/PMC7356191/ /pubmed/32429088 http://dx.doi.org/10.3390/vision4020027 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sørensen, Jakob Ø.
Subhi, Yousif
Molbech, Christopher R.
Krogh Nielsen, Marie
Sørensen, Torben L.
Plasma Levels of Matrix Metalloprotease MMP-9 and Tissue Inhibitor TIMP-1 in Caucasian Patients with Polypoidal Choroidal Vasculopathy
title Plasma Levels of Matrix Metalloprotease MMP-9 and Tissue Inhibitor TIMP-1 in Caucasian Patients with Polypoidal Choroidal Vasculopathy
title_full Plasma Levels of Matrix Metalloprotease MMP-9 and Tissue Inhibitor TIMP-1 in Caucasian Patients with Polypoidal Choroidal Vasculopathy
title_fullStr Plasma Levels of Matrix Metalloprotease MMP-9 and Tissue Inhibitor TIMP-1 in Caucasian Patients with Polypoidal Choroidal Vasculopathy
title_full_unstemmed Plasma Levels of Matrix Metalloprotease MMP-9 and Tissue Inhibitor TIMP-1 in Caucasian Patients with Polypoidal Choroidal Vasculopathy
title_short Plasma Levels of Matrix Metalloprotease MMP-9 and Tissue Inhibitor TIMP-1 in Caucasian Patients with Polypoidal Choroidal Vasculopathy
title_sort plasma levels of matrix metalloprotease mmp-9 and tissue inhibitor timp-1 in caucasian patients with polypoidal choroidal vasculopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356191/
https://www.ncbi.nlm.nih.gov/pubmed/32429088
http://dx.doi.org/10.3390/vision4020027
work_keys_str_mv AT sørensenjakobø plasmalevelsofmatrixmetalloproteasemmp9andtissueinhibitortimp1incaucasianpatientswithpolypoidalchoroidalvasculopathy
AT subhiyousif plasmalevelsofmatrixmetalloproteasemmp9andtissueinhibitortimp1incaucasianpatientswithpolypoidalchoroidalvasculopathy
AT molbechchristopherr plasmalevelsofmatrixmetalloproteasemmp9andtissueinhibitortimp1incaucasianpatientswithpolypoidalchoroidalvasculopathy
AT kroghnielsenmarie plasmalevelsofmatrixmetalloproteasemmp9andtissueinhibitortimp1incaucasianpatientswithpolypoidalchoroidalvasculopathy
AT sørensentorbenl plasmalevelsofmatrixmetalloproteasemmp9andtissueinhibitortimp1incaucasianpatientswithpolypoidalchoroidalvasculopathy